Aethlon Medical Inc (AEMD) stock
AEMDNasdaqPharmaceutical PreparationsFiscal year ends March 31
$5.11+0.03 (+0.59%)
Close on Nov 18, 2026Market cap $3.63MP/E –Yield –
Aethlon Medical r&d expenses
Research and development expenses are spending on new products and technology.
Aethlon Medical's R&D Expenses for the twelve months ending Mar 31, 2026 was $1.91M, down 13.6% year over year. For fiscal 2026 it was $1.91M, down 13.6% from the year before. Over ten years it grew 9.4% a year on average. The highest annual figure on record is $2.75M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $1.91M | -13.6% |
| FY2025 | Mar 31, 2025 | $2.21M | -12.2% |
| FY2024 | Mar 31, 2024 | $2.52M | -8.2% |
| FY2023 | Mar 31, 2023 | $2.75M | +17.3% |
| FY2022 | Mar 31, 2022 | $2.34M | +13.0% |
| FY2021 | Mar 31, 2021 | $2.07M | +123.5% |
| FY2020 | Mar 31, 2020 | $927.00K | +3.5% |
| FY2019 | Mar 31, 2019 | $896.00K | +52.9% |
| FY2018 | Mar 31, 2018 | $586.00K | -12.9% |
| FY2017 | Mar 31, 2017 | $673.00K | -13.9% |
| FY2016 | Mar 31, 2016 | $782.00K | -23.9% |
| FY2015 | Mar 31, 2015 | $1.03M | -31.9% |
| FY2014 | Mar 31, 2014 | $1.51M | +4.8% |
| FY2013 | Mar 31, 2013 | $1.44M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $549.00K | +128.6% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $589.98K | +125.6% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $524.00K | +26.4% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $1.33M | +106.0% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $240.20K | -59.5% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $261.49K | -58.4% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $414.66K | -38.9% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $644.89K | +4.8% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $593.40K | +6.3% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $628.45K | -26.3% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $678.92K | -20.9% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $615.62K | -34.3% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $558.22K | +57.4% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $852.46K | +78.3% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $858.35K | +46.1% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $937.11K | +33.0% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $354.57K | -23.1% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $478.20K | -6.0% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $587.69K | +55.8% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $704.67K | +199.9% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $461.18K | +111.0% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $508.90K | +128.4% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $377.17K | +51.6% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $234.98K | -2.2% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $218.57K | -10.4% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $222.86K | +24.6% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $248.87K | +27.8% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $240.24K | +94.7% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $243.84K | +88.7% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $178.80K | +6.1% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $194.78K | +23.7% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $123.36K | -29.9% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $129.21K | -27.6% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $168.57K | -49.4% |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $157.46K | +33.8% |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $175.93K | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $178.44K | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | $333.43K | – |
| Q1 FY2017CQ2 2016 | Jun 30, 2016 | $117.66K | – |
See a number that looks wrong?